Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHT-AML
NCT07084584Phase 1Withdrawn
- Sponsor
- Galecto, Inc.
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of GB3226 in acute myeloid leukemia (AML) (3 cohorts), sponsored by Galecto, Inc. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events at 28 days and 2 more. Planned start Jun 2026; status: withdrawn.
02
Drugs
GB3226
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07084584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07084584.